For research use only. Not for therapeutic Use.
LY3509754（Cat No.:I044434）is a humanized monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein receptor (LDLR) degradation. By inhibiting PCSK9, LY3509754 enhances LDLR recycling and increases the clearance of LDL cholesterol from the bloodstream. It is developed as a long-acting therapeutic candidate for hypercholesterolemia and other lipid disorders. LY3509754 has shown extended duration of action and favorable pharmacokinetics in preclinical and early clinical studies, supporting its potential for less frequent dosing compared to existing PCSK9 inhibitors. It contributes to cardiovascular disease research and lipid-lowering therapy development.
| CAS Number | 2452464-73-0 |
| Synonyms | N-[(S)-(4,4-difluorocyclohexyl)-[7-[(1S)-2-methoxy-1-[(4S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl]ethyl]imidazo[1,2-b]pyridazin-2-yl]methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide |
| Molecular Formula | C24H27F5N8O4 |
| Purity | ≥95% |
| IUPAC Name | N-[(S)-(4,4-difluorocyclohexyl)-[7-[(1S)-2-methoxy-1-[(4S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl]ethyl]imidazo[1,2-b]pyridazin-2-yl]methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide |
| InChI | InChI=1S/C24H27F5N8O4/c1-12-19(35-41-34-12)21(38)33-20(13-3-5-23(25,26)6-4-13)15-9-37-18(31-15)7-14(8-30-37)16(11-40-2)36-10-17(24(27,28)29)32-22(36)39/h7-9,13,16-17,20H,3-6,10-11H2,1-2H3,(H,32,39)(H,33,38)/t16-,17+,20+/m1/s1 |
| InChIKey | MVWVCLAORBNXSD-UWVAXJGDSA-N |
| SMILES | CC1=NON=C1C(=O)N[C@@H](C2CCC(CC2)(F)F)C3=CN4C(=N3)C=C(C=N4)[C@@H](COC)N5C[C@H](NC5=O)C(F)(F)F |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
